The Influence of Chronic Exposure to Antipsychotic Medications on Brain Size before and after Tissue Fixation: A Comparison of Haloperidol and Olanzapine in Macaque Monkeys

It is unclear to what degree antipsychotic therapy confounds longitudinal imaging studies and post-mortem studies of subjects with schizophrenia. To investigate this problem, we developed a non-human primate model of chronic antipsychotic exposure. Three groups of six macaque monkeys each were exposed to oral haloperidol, olanzapine or sham for a 17–27 month period. The resulting plasma drug levels were comparable to those seen in subjects with schizophrenia treated with these medications. After the exposure, we observed an 8–11% reduction in mean fresh brain weights as well as left cerebrum fresh weights and volumes in both drug-treated groups compared to sham animals. The differences were observed across all major brain regions (frontal, parietal, temporal, occipital, and cerebellum), but appeared most robust in the frontal and parietal regions. Stereological analysis of the parietal region using Cavalieri's principle revealed similar volume reductions in both gray and white matter. In addition, we assessed the subsequent tissue shrinkage due to standard histological processing and found no evidence of differential shrinkage due to drug exposure. However, we observed a pronounced general shrinkage effect of ∼20% and a highly significant variation in shrinkage across brain regions. In conclusion, chronic exposure of non-human primates to antipsychotics was associated with reduced brain volume. Antipsychotic medication may confound post-mortem studies and longitudinal imaging studies of subjects with schizophrenia that depend upon volumetric measures.

[1]  Bente Pakkenberg,et al.  Stereological quantitation in cerebella from people with schizophrenia , 2003, British Journal of Psychiatry.

[2]  H. Haug.  History of neuromorphometry , 1986, Journal of Neuroscience Methods.

[3]  J. Rapoport,et al.  Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Metz,et al.  Effect of Alosetron (a New 5‐HT3 Receptor Antagonist) on the Pharmacokinetics of Haloperidol in Schizophrenic Patients , 1995, Journal of clinical pharmacology.

[5]  R. Kahn,et al.  The Effect of Clozapine on Caudate Nucleus Volume in Schizophrenic Patients Previously Treated with Typical Antipsychotics , 2001, Neuropsychopharmacology.

[6]  T. Gillespie,et al.  Disposition and biotransformation of the antipsychotic agent olanzapine in humans. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[7]  S. Heckers,et al.  Hippocampal neuron number in schizophrenia. A stereological study. , 1991, Archives of general psychiatry.

[8]  David A Lewis,et al.  The Human Brain Revisited: Opportunities and Challenges in Postmortem Studies of Psychiatric Disorders , 2002, Neuropsychopharmacology.

[9]  A. Sampson,et al.  Stereological analysis of the mediodorsal thalamic nucleus in schizophrenia: Volume, neuron number, and cell types , 2004, The Journal of comparative neurology.

[10]  R. Littell.  SAS System for Mixed Models , 1996 .

[11]  V. Howard,et al.  Unbiased Stereology: Three-Dimensional Measurement in Microscopy , 1998 .

[12]  J. Lieberman,et al.  Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. , 1994, The American journal of psychiatry.

[13]  Paul J. Harrison,et al.  A postmortem study of the mediodorsal nucleus of the thalamus in schizophrenia , 2003, Schizophrenia Research.

[14]  O. Olesen,et al.  Determination of olanzapine in serum by high-performance liquid chromatography using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[15]  J. Lieberman,et al.  Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. , 2004, The American journal of psychiatry.

[16]  A. Sampson,et al.  Pyramidal cell size reduction in schizophrenia: evidence for involvement of auditory feedforward circuits , 2004, Biological Psychiatry.

[17]  V. Barnett,et al.  Applied Linear Statistical Models , 1975 .

[18]  David A Lewis,et al.  Reduced Pyramidal Cell Somal Volume in Auditory Association Cortex of Subjects with Schizophrenia , 2003, Neuropsychopharmacology.

[19]  A. Sampson,et al.  Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. , 1999, The American journal of psychiatry.

[20]  Y. Okubo,et al.  A review of MRI studies of progressive brain changes in schizophrenia. , 2001, Journal of medical and dental sciences.

[21]  F. Benes,et al.  Reduced neuronal size in posterior hippocampus of schizophrenic patients. , 1991, Schizophrenia bulletin.

[22]  B. Pakkenberg,et al.  No deficit in total number of neurons in the prefrontal cortex in schizophrenics. , 2001, Journal of psychiatric research.

[23]  H. Gundersen,et al.  The efficiency of systematic sampling in stereology — reconsidered , 1999, Journal of microscopy.

[24]  D. Greenblatt,et al.  Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study. , 1986 .

[25]  Sabine Landau,et al.  Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. , 2002, Cerebral cortex.

[26]  L. Selemon,et al.  Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder , 2001, Biological Psychiatry.

[27]  N C Andreasen,et al.  Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. , 1999, The American journal of psychiatry.

[28]  H J Gundersen,et al.  The efficiency of systematic sampling in stereology and its prediction * , 1987, Journal of microscopy.

[29]  A. Denman,et al.  Schizophrenia (2nd edn) , 2004, British Journal of Psychiatry.

[30]  Paul J. Harrison,et al.  Meta-analysis of brain weight in schizophrenia , 2003, Schizophrenia Research.

[31]  D. German,et al.  Elevated neuron number in the limbic thalamus in major depression. , 2004, The American journal of psychiatry.

[32]  B. Pakkenberg,et al.  Total length of nerve fibers in prefrontal and global white matter of chronic schizophrenics. , 2003, Journal of psychiatric research.

[33]  J. Lieberman,et al.  Striatal Volume Changes in the Rat Following Long-term Administration of Typical and Atypical Antipsychotic Drugs , 2002, Neuropsychopharmacology.

[34]  G. Sedvall,et al.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.

[35]  K. Krishnan,et al.  Neuroleptic treatment and caudate plasticity , 1995, The Lancet.

[36]  Jay N Giedd,et al.  Progressive brain volume loss during adolescence in childhood-onset schizophrenia. , 2003, The American journal of psychiatry.

[37]  Bente Pakkenberg,et al.  Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. , 2004, The American journal of psychiatry.

[38]  John Suckling,et al.  For personal use. Only reproduce with permission from The Lancet Publishing Group. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy , 2002 .

[39]  J. Nyengaard,et al.  Stereological estimates of number and length of capillaries in subdivisions of the human hippocampal region , 2001, Hippocampus.

[40]  C. Beasley,et al.  Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. , 1997, Journal of clinical psychopharmacology.

[41]  A. Sampson,et al.  Decreased somal size of deep layer 3 pyramidal neurons in the prefrontal cortex of subjects with schizophrenia. , 2001, Archives of general psychiatry.

[42]  A. Tamhane,et al.  Multiple Comparison Procedures , 1989 .

[43]  B. Lund,et al.  Olanzapine Plasma Concentrations and Clinical Response: Acute Phase Results of the North American Olanzapine Trial , 2001, Journal of clinical psychopharmacology.

[44]  Alan A. Wilson,et al.  5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. , 1998, The American journal of psychiatry.

[45]  W. Scherle,et al.  A simple method for volumetry of organs in quantitative stereology. , 1970, Mikroskopie.

[46]  Michael H. Kutner.  Applied Linear Statistical Models , 1974 .

[47]  S M Mendis-Handagama,et al.  Sources of error in the estimation of Leydig cell numbers in control and atrophied mammalian testes , 1990, Journal of microscopy.

[48]  S. Kapur,et al.  Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. , 2001, The American journal of psychiatry.

[49]  H. Gundersen,et al.  MRI volume measurements of hypointense objects A phantom study using stereological methods , 2002, Journal of Neuroscience Methods.

[50]  J. Trojanowski,et al.  Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. , 1995, The American journal of psychiatry.

[51]  H. Keselman,et al.  Multiple Comparison Procedures , 2005 .

[52]  H J Gundersen,et al.  How accurate are measurements on MRI? a study on multiple sclerosis using reliable 3D stereological methods , 1999, Journal of magnetic resonance imaging : JMRI.

[53]  R. Emsley,et al.  A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. , 2004, The international journal of neuropsychopharmacology.

[54]  R. Gur,et al.  Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. , 1998, The American journal of psychiatry.

[55]  P. Goldman-Rakic,et al.  Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. , 1998, Archives of general psychiatry.

[56]  R. Kerwin,et al.  Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. , 2001, Archives of general psychiatry.

[57]  S. Kapur,et al.  Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. , 2000, The American journal of psychiatry.

[58]  Paul J. Harrison.  The neuropathology of schizophrenia , 2008 .

[59]  Vincent Magnotta,et al.  Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. , 2003, Archives of general psychiatry.

[60]  C. Halldin,et al.  D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. , 1995, The American journal of psychiatry.

[61]  P. Goldman-Rakic,et al.  Smaller frontal gray matter volume in postmortem schizophrenic brains. , 2002, The American journal of psychiatry.

[62]  S. Steingard,et al.  Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. , 1991, Archives of general psychiatry.

[63]  T. Gillespie,et al.  Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[64]  R. McCarley,et al.  A review of MRI findings in schizophrenia , 2001, Schizophrenia Research.

[65]  S. Kapur,et al.  Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. , 1999, The American journal of psychiatry.

[66]  Manzar Ashtari,et al.  Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine , 1995, The Lancet.

[67]  S. Weis,et al.  Vascular changes in the cerebral cortex in HIV-1 infection , 1996, Acta Neuropathologica.

[68]  B. Pakkenberg,et al.  Total nerve cell number in neocortex in chronic schizophrenics and controls estimated using optical disectors , 1993, Biological Psychiatry.

[69]  Bente Pakkenberg,et al.  Comparison of MR imaging against physical sectioning to estimate the volume of human cerebral compartments , 2003, NeuroImage.

[70]  S. Kapur,et al.  The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study , 1997, Psychopharmacology.

[71]  H. Nicolini,et al.  Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine. , 2003, The international journal of neuropsychopharmacology.

[72]  Marek Kubicki,et al.  Recent structural and functional imaging findings in schizophrenia , 2003 .

[73]  Philip D. Harvey,et al.  White matter changes in schizophrenia: evidence for myelin-related dysfunction. , 2003, Archives of general psychiatry.

[74]  B. Pakkenberg,et al.  Post-mortem Study of Chronic Schizophrenic Brains , 1987, British Journal of Psychiatry.

[75]  D. Mikulis,et al.  Caudate volume changes in first episode psychosis parallel the effects of normal aging: a 5-year follow-up study , 2002, Schizophrenia Research.

[76]  P. Goldman-Rakic,et al.  Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure , 1999, Biological Psychiatry.

[77]  M. Keshavan,et al.  Changes in caudate volume with neuroleptic treatment , 1994, The Lancet.

[78]  Patrick R Hof,et al.  Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia , 2003, Biological Psychiatry.

[79]  H. Budka,et al.  Vascular changes in the cerebral cortex in HIV-1 infection: I. A morphometric investigation by light and electron microscopy. , 1996, Clinical neuropathology.

[80]  J. Pierri,et al.  Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. , 1999, The American journal of psychiatry.

[81]  Christer Halldin,et al.  Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients , 1993, Biological Psychiatry.

[82]  Paul J. Harrison.  Neuropathology of schizophrenia , 2005 .